Sharing our research on the global stage at 2021 ASCO Annual Meeting

Sharing our research on the global stage at 2021 ASCO Annual Meeting

7 June 2021

Research from MIA was once again in the spotlight as findings were shared at the virtual ASCO21 - the world’s largest professional oncology meeting.

In addition to the recent story revealing the success of a new immunotherapy trial for melanoma, another 14 abstracts involving our researchers were shared at the conference on the weekend. Here is a snapshot of just a few findings: 

Managing immune-related side effects

Treatment of melanoma with immunotherapy can be lifesaving; however, it can also be complicated by significant side effects as the activated immune system cells may attack healthy cells as well. Most of the side effects occur in the skin, liver, bowel, thyroid gland and lungs, though any organ can be affected.

Immune cells communicate by producing small proteins, called ‘cytokines’, which co-ordinate the body’s response against inflammation. Sometimes this response can go into overdrive, resulting in increased levels of cytokines, making the inflammation worse.

Medical Oncologist Dr Florentia Dimitriou and colleagues identified a cytokine, known as IL-6, which is increased in many inflammatory conditions, including viral infections, like COVID-19, and rheumatoid diseases, such as rheumatoid arthritis.

“We used a specific drug that blocks IL-6, known as tocilizumab, and found the drug reduced the inflammation and lessened the symptoms in these patients,” said Dr Dimitriou. “Based on this observation, the drug we used specifically blocks the activated cytokines and controls the inflammation, without suppressing the immune system.”

Management of Stage III/IV melanoma with immunotherapy after surgery

Immunotherapy after surgery for Stage III melanoma has become the standard treatment approach. Research from Clinical Nurse Consultant Rebecca Johnson and colleagues aimed to understand who is being treated with immunotherapy across Australia, how effective the treatment was, and the variety of treatment options that are implemented if the melanoma recurs.

“Overall, we found the efficacy of treatment was similar to the clinical trials,” said Ms Johnson. “For most patients with melanoma recurrence, there was evidence of disease in distant organs within two years of recurrence. Across the study, these patients were treated with a variety of treatment options.”

Progression on combination immunotherapy

Research from MIA’s Medical Oncologist Dr Ines Silva and her team focussed on patients whose disease progressed after first being treated with combination immunotherapy - drugs that stimulate immune cells to fight cancer. Although around half of these patients are still alive five years after starting treatment, the majority of patients will progress and may require further treatment.

“We looked at how patients’ disease progressed from first-line treatment with a combination of anti-PD1 therapy and ipilimumab, and then determined management strategies for these patients,” said Dr Silva.

“We have shown that in a group of patients, therapy that targets BRAF mutant melanoma, rechallenged with anti-PD1 alone or in combination with ipilimumab and investigational drugs (in clinical trials), showed activity in this setting, and can be considered a treatment option in this context; chemotherapy has no role in these patients.”

Understanding the importance of radiotherapy after surgery in the modern era of immunotherapy

When melanoma spreads from the skin to nearby lymph nodes, the chances of melanoma coming back after it is surgically removed can be quite high for some patients. In this situation, radiotherapy can be given after surgery to the nearby lymph node area to reduce the chance of melanoma returning.

In an era where immunotherapy is now often given to reduce recurrence after surgery, Medical Oncologist Dr Prachi Bhave and colleagues at MIA investigated whether adjuvant radiotherapy is still effective in reducing melanoma recurrence. The study found that radiotherapy significantly reduced the risk of melanoma returning in nearby lymph nodes, and therefore continues to have a role in some patients whose melanoma has returned despite receiving immunotherapy after surgery.

To find out more about the leading research from MIA that was presented at ASCO, you can read their poster presentations here or see abstracts here.

#ASCO21

Tune into Jay's Longest Melanoma March Channel 10 documentary
16 Sep 2019

Tune into Jay's Longest Melanoma March Channel 10 documentary

Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.

Professor Georgina Long Co-Medical Director named Women of Influence in Australian Financial Review Top 100 List
11 Sep 2019

Professor Georgina Long Co -Medical Director named Women of Influence in AFR Top 100 List

We are proud to announce that our Professor Georgina Long Co -Medical Director Melanoma Institute Australia has been named in the Top 100 Financial Review 2019 Women of Influence.

Community Fundraising August Wrap-Up
04 Sep 2019

Community Fundraising August Wrap-Up

It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships
02 Sep 2019

From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships

They are a formidable team - in work and in play  –  and one set to make history on both fronts.

Melanoma Institute Australia hosts first SunSafe Student Ambassador Program for 2019
30 Aug 2019

Melanoma Institute Australia hosts SunSafe Student Ambassador Programs 2019

This week, Melanoma Institute Australia hosted the first of six SunSafe Student Ambassador Programs for 2019.

Tags: SunSafe
Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma
23 Aug 2019

Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma

Federal government urged to provide certainty of access to immunotherapy for high risk melanoma patients.

Team Melanoma smashes City2Surf
16 Aug 2019

Team Melanoma smashes City2Surf

We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!

Ready to run over melanoma at City2Surf 2019
08 Aug 2019

Ready to run over melanoma at City2Surf 2019

Lauren O'Brien tells us why she's running for a cause close to her heart

Community Fundraising July Wrap-Up
01 Aug 2019

Community Fundraising July Wrap-Up

MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in the month of July that are helping us move closer to our goal of zero deaths from melanoma.

Breast cancer drug may hold key to tackling most deadly type of melanoma
23 Jul 2019

Breast cancer drug may hold key to tackling most deadly type of melanoma

An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a type of breast cancer may hold the key to treating an aggressive and deadly form of melanoma.

MIA takes centre stage at leading cancer conference
05 Jun 2019

MIA takes centre stage at leading cancer conference

Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma is treated .

International Clinical Trials Day 2019
20 May 2019

International Clinical Trials Day 2019

Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.

Emma Betts' legacy will live on
17 May 2019

Emma Betts' legacy will live on

“I’m the age Emma was when she passed away. It almost feels unfair, that she has to not be here for me to be able to do this. But I will use this opportunity to push as hard as I can to reach our collective goal of zero deaths from melanoma.”

Support PBS listing for three adjuvant treatments of resected Stage III melanoma
13 May 2019

Support PBS listing for three adjuvant treatments of resected Stage III melanoma

As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.

Support PBS listing for pembrolizumab
06 May 2019

Support PBS listing for pembrolizumab

As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.

How are the Premier's Awards helping cancer researchers?
02 May 2019

How are the Premier's Awards helping cancer researchers?

MIA had four winners in the 2017 Premiers Awards. Find out how winning has influenced their work over the past year.

Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects
19 Mar 2019

Cancer Council awards Melanoma Institute Australia researchers funding for ground-breaking cancer research projects

Almost $9 million of new funding was awarded to 13 ground-breaking cancer research projects at the 2019 Cancer Council NSW Research Awards.

Making a difference to many
15 Mar 2019

Making a difference to many

Georgina V. Long is co-medical director of Melanoma Institute Australia and Chair of Melanoma Medical Oncology and Translational Research. She is the first woman president of the Society for Melanoma Research.

Aussie icon Sophie Monk calls on Australians to get behind Melanoma March
26 Feb 2019

Aussie icon Sophie Monk calls on Australians to get behind Melanoma March

Quintessential Aussie girl and media personality Sophie Monk has been announced as a National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.

Melanoma breakthrough paves way for personalised treatment for all cancer patients
14 Feb 2019

Melanoma breakthrough paves way for personalised treatment for all cancer patients

Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.